Yu Hang, Gao Daoyuan, You Guoxing, Li Weidan, Wang Ying, Chen Yuzhi, Zhao Lian
Academy of Military Medical Sciences, Academy of Military Science of the Chinese People's Liberation Army, Beijing, China.
Front Bioeng Biotechnol. 2024 Jun 28;12:1376806. doi: 10.3389/fbioe.2024.1376806. eCollection 2024.
Red blood cell substitutes offer a solution to the problem of blood shortage and side effects of blood transfusion. Hemoglobin-based oxygen carriers (HBOCs) are one of the promising substitutes for red blood cells. Vasoactivity, which refers to the side effect of HBOCs that causes vasoconstriction and subsequent hypertension, limits the clinical application of HBOCs. In this study, an method for the evaluation of vasoactivity induced by HBOCs was established based on isolated rat mesenteric artery vessels and the DMT120CP system. The DMT120CP system, equipped with a flowmeter, permits the control of intravascular pressure, pressure gradient, and flow conditions with high accuracy, simulating the physiological conditions for isolated vessels. The concentration of noradrenaline was optimized to 1 × 10∼3 × 10 M. PEGylated bovine hemoglobin (PEG-bHb) was synthesized and perfused into the vessel for vasoactivity evaluation, with bHb as the positive control and PSS buffer solution as the negative control. PEG-bHb showed a hydration diameter of 15.5 ± 1.4 nm and a P value of 6.99 mmHg. PEG-bHb exhibited a colloid osmotic pressure of 64.1 mmHg and a viscosity of 1.73 cp at 40 mg/mL. The established vasoactivity evaluation method showed significant differences in samples (bHb or PEG-bHb) with different vasoactivity properties. The vasoconstriction percentage induced by PEG-bHb samples synthesized in different batches showed coefficients of variation less than 5%, indicating good applicability and repeatability. The established evaluation method can be applied to study the vasoactivity induction and elimination strategies, promoting the clinical application of HBOCs.
红细胞替代物为血液短缺和输血副作用问题提供了解决方案。基于血红蛋白的氧载体(HBOCs)是红细胞有前景的替代物之一。血管活性是指HBOCs引起血管收缩及随后高血压的副作用,这限制了HBOCs的临床应用。在本研究中,基于离体大鼠肠系膜动脉血管和DMT120CP系统建立了一种评估HBOCs诱导血管活性的方法。配备流量计的DMT120CP系统能够高精度地控制血管内压力、压力梯度和血流状况,模拟离体血管的生理条件。去甲肾上腺素的浓度优化为1×10~3×10 M。合成了聚乙二醇化牛血红蛋白(PEG-bHb)并灌注到血管中进行血管活性评估,以bHb作为阳性对照,PSS缓冲溶液作为阴性对照。PEG-bHb的水化直径为15.5±1.4 nm,P值为6.99 mmHg。PEG-bHb在40 mg/mL时表现出64.1 mmHg的胶体渗透压和1.73 cp的粘度。所建立的血管活性评估方法在具有不同血管活性特性的样品(bHb或PEG-bHb)中显示出显著差异。不同批次合成的PEG-bHb样品诱导的血管收缩百分比变异系数小于5%,表明具有良好的适用性和可重复性。所建立的评估方法可用于研究血管活性诱导和消除策略,促进HBOCs的临床应用。